FORMULARY v2026.05.06 NEXT REVISION 2026-08-04 CCH-001 OPEN CCH-002 OPEN · 3 SLOTS CCH-003 WAITLIST 11d CCH-004 OPEN CCH-005 OPEN CCH-006 LIMITED ERRATA: 14 ENTRIES SINCE 2024-Q2 BEGIN INTAKE OPEN ⟶ FORMULARY v2026.05.06 NEXT REVISION 2026-08-04 CCH-001 OPEN CCH-002 OPEN · 3 SLOTS CCH-003 WAITLIST 11d CCH-004 OPEN CCH-005 OPEN CCH-006 LIMITED ERRATA: 14 ENTRIES SINCE 2024-Q2 BEGIN INTAKE OPEN ⟶
Errata · v2026.05.06

Where the formulary was wrong, and when we changed it.

Every material change to a monograph since the practice opened, dated, named, and linked to the prior text. Fourteen entries since 2024 Q2; the older log is on request from the front desk and is preserved electronically.

Total errata
27 (since 2020) · 14 since 2024-Q2
Cadence
Quarterly bulk · individual as needed
Convention
Following ICMJE — Corrections, Retractions, and Version Control
Search
Anchored by monograph code (#cch-001-…)

Errata are organized by monograph. Within each monograph, entries appear in reverse chronological order. Each entry names the date, the field affected, the prior text (briefly), the revised text, and the reason for the change.

CCH-001 — Adult primary care

2026-04-22 · v2026.04 → supersedes v2026.01.15

§ Adverse effects. Added explicit exclusion for patients hospitalized for decompensated heart failure within 12 months. Reason: internal review found two such patients had been accepted in 2024 without coordinated heart-failure-clinic referral; outcomes were acceptable but the responsibility was unclear.

§ Outcomes. Refreshed table with 2026 Q1 numbers. Reason: standard quarterly update.

§ Cost. DPC family-additional rate clarified from ambiguous "$25–$35" to $25 flat. Reason: ambiguity flagged by three intake patients in v2026.01 cycle.

2026-01-15 · v2026.01 → supersedes v2025.10.30

§ Indications. Updated PrEP language to align with current CDC PrEP clinician guidance (long-acting cabotegravir option mentioned).

§ Mechanism. Changed virtual-follow-up suitability language to allow titration visits when home BP monitoring is in place.

2025-08-04 · v2025.08 → supersedes v2025.05

§ Patient counseling. Added the explicit "we will print the questions before the room" sentence. Reason: Maritza pointed out we had been doing it for a year without writing it down.

CCH-002 — Pediatric & adolescent

2026-03-15 · v2026.03 → supersedes v2026.01.10

§ Mechanism. Clarified that lactation visits are not separately billed within the well-child schedule. Reason: billing-office query.

§ Contraindications, item 3. Reworded to emphasize that delayed-but-completing immunization schedules are welcome (the previous text was widely misread as excluding any deviation from the standard schedule). Reason: two confused intake calls; rewrite by Helena Rey.

2025-11-08 · v2025.11 → supersedes v2025.08

§ Indications. Added explicit ADHD evaluation pathway language. Reason: we had been performing the evaluation but had not documented it as scope.

CCH-003 — Behavioral health

2026-04-30 · v2026.04 → supersedes v2026.01.20

§ Mechanism. Updated current waitlist from 14 days to 11 days. Reason: standard quarterly update; the cover ticker is the live version.

§ Outcomes. 6-month MOUD retention updated from 68% to 72%. Reason: Q1 2026 audit.

2025-10-12 · v2025.10 → supersedes v2025.07

§ Adverse effects. Added explicit benzodiazepine policy (we will continue tapers, not initiate long-term). Reason: a single intake misunderstood our willingness to continue an established taper as willingness to initiate.

CCH-004 — Reproductive & gender

2026-04-12 · v2026.04 → supersedes v2026.01.05

§ Indications. Updated to cite the 2024 CDC US MEC for contraception. Reason: external citation refresh.

§ Mechanism. Reworded the GAHT section to be explicit about the informed-consent model. Reason: the prior text described what we did but did not name the model; the bulletin "Menopause intake rewrite" prompted a closer reading.

2025-12-15 · v2025.12

§ Mechanism. Postpartum mental-health screening moved from 4-week to 2-week post-discharge phone call, ahead of the in-person 4-week visit. Reason: case log CL-2025-022 identified that the 4-week timing was later than ACOG 2023 guidance recommends.

CCH-005 — Office procedures

2026-02-28 · v2026.02 → supersedes v2025.10.30

§ Outcomes. Refreshed full-year CY 2025 procedure complication numbers.

§ Indications. Added Skyla and Kyleena alongside Mirena and Liletta.

§ Patient counseling. Added explicit pre-procedure ibuprofen recommendation for IUC. Reason: internal review found this had not been documented as a default.

CCH-006 — Acute & after-hours

2026-04-30 · v2026.04 → supersedes v2026.01.20

§ Outcomes. Added 30-day readmission tracking (was previously only same-day-access).

§ Mechanism. On-call rotation explicitly named.

§ Adverse effects. Clarified the >3-acute-visits-in-90-days policy.

2025-09-22 · v2025.09

§ Mechanism. After-hours line window changed from 18:00–22:00 to 17:30–22:00 to match actual close-of-day pager handoff.

Earlier errata (pre-2024-Q2)

The earlier errata log — 13 entries between 2020 and Q1 2024 — is preserved electronically and is available on request to front@pharos-kingston.example or by phone at (845) 555-0142. We have not posted it here because the older monograph schema (which used a different field order) is too different from the current schema to map cleanly into the format above; rather than retrofit, we have left the old log in its original form. The corresponding old monograph text is preserved alongside.

For the methodology behind the errata page, see the bulletin "On Wadar, errata, and the discipline of public correction".